NUVL

NUVL

USD

Nuvalent Inc. Class A Common Stock

$92.690-1.560 (-1.655%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$94.250

Haut

$95.225

Bas

$92.075

Volume

0.28M

Fondamentaux de l'Entreprise

Capitalisation Boursière

6.7B

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

0.46M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $55.535Actuel $92.690Haut $104.9

Actualités Connexes

PR Newswire

Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

Voir plus
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
Analyst Upgrades

UBS Maintains Buy on Nuvalent, Raises Price Target to $132

UBS analyst David Dai maintains Nuvalent with a Buy and raises the price target from $114 to $132.

Voir plus
UBS Maintains Buy on Nuvalent, Raises Price Target to $132
PR Newswire

Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

Voir plus
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results
Analyst Upgrades

Piper Sandler Maintains Overweight on Nuvalent, Raises Price Target to $128

Piper Sandler analyst Kelsey Goodwin maintains Nuvalent with a Overweight and raises the price target from $112 to $128.

Voir plus
Piper Sandler Maintains Overweight on Nuvalent, Raises Price Target to $128

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.